Dong-A Receives US FDA Approval on Phase II Clinical Trial for DA-8159

Dong-A Pharmaceutical said its novel medication for male erectile dysfunction (ED) treatment, under a codename DA-8159, has received an approval for Phase II clinical trial by the United States Food and Drug Administration (FDA).

With the approval, the company expects that the Phase II clinical trial for DA-8159 in the United States will be completed by Year 2006, and the NDA (New Drug Appli...